Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 10 2022
01 10 2022
Historique:
pubmed:
19
7
2022
medline:
9
9
2022
entrez:
18
7
2022
Statut:
ppublish
Résumé
Metabolic risk factors and nonalcoholic fatty liver disease (NAFLD) in people with HIV (PWH) have been increasing. Patients exhibiting the inflammatory subtype nonalcoholic steatohepatitis (NASH) are at increased risk of liver-related complications. Therefore, the aim was to investigate the prevalence of NASH with significant fibrosis in PWH using noninvasive tests (NITs). In this prospectively enrolling cohort study, 282 PWH were explored for hepatic steatosis, fibrosis and steatohepatitis using vibration-controlled transient elastography (VCTE) and the Fibroscan-AST (FAST) score. On the basis of controlled attenuation parameter (CAP; dB/m) and liver stiffness measurement (LSM; kPa), patients were categorized according to the presence of steatosis (≥275 dB/m) and significant fibrosis (≥8.2 kPa). The FAST score was calculated according to established cut-offs. The prevalence of hepatic steatosis in this cohort was 35.5% ( n = 100) with 75 (75%) of these patients fulfilling the criteria of NAFLD. The prevalence of significant fibrosis (≥ F2) was 6.7% ( n = 19). The FAST score identified a total of 32 (12.3%) patients with a cut-off greater than 0.35, of whom 28 (87.5%) PWH qualified as NASH. On multivariable analysis, waist circumference was a predictor of hepatic steatosis and type 2 diabetes was a predictor of significant fibrosis. Type 2 diabetes and ALT remained independent predictors of a FAST score greater than 0.35. NASH with significant fibrosis is highly prevalent among PWH. The FAST score may be helpful to identify patients at risk for significant liver disease.
Identifiants
pubmed: 35849074
doi: 10.1097/QAD.0000000000003312
pii: 00002030-202210010-00006
pmc: PMC9451864
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1665-1674Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1 . Lancet 1998; 352:1725–1730.
Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, et al. Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study . AIDS (London, England) 2010; 24:1537–1548.
Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection . AIDS 2017; 31:1621–1632.
Hernando V, Perez-Cachafeiro S, Lewden C, Gonzalez J, Segura F, Oteo JA, et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection . J Hepatol 2012; 57:743–751.
Konopnicki D, Mocroft A, Wit Sde, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort . AIDS 2005; 19:593–601.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes . Hepatology 2016; 64:73–84.
Schattenberg JM, Lazarus JV, Newsome PN, Serfaty L, Aghemo A, Augustin S, et al. Disease burden and economic impact of diagnosed nonalcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis . Liver Int 2021; 41:1227–1242.
Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis . N Engl J Med 2017; 377:2063–2072.
Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis . Hepatology 2017; 65:1557–1565.
Bonfanti P, Giannattasio C, Ricci E, Facchetti R, Rosella E, Franzetti M, et al. HIV and metabolic syndrome: a comparison with the general population . J Acquir Immune Defic Syndr 2007; 45:426–431.
Squillace N, Soria A, Bozzi G, Gori A, Bandera A. Nonalcoholic fatty liver disease and steatohepatitis in people living with HIV . Expert Rev Gastroenterol Hepatol 2019; 13:643–650.
Surial B, Mugglin C, Calmy A, Cavassini M, Günthard HF, Stöckle M, et al. Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study . Ann Intern Med 2021; 174:758–767.
Vuille-Lessard É, Lebouché B, Lennox L, Routy J-P, Costiniuk CT, Pexos C, et al. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients . AIDS 2016; 30:2635–2643.
Bischoff J, Gu W, Schwarze-Zander C, Boesecke C, Wasmuth J-C, van Bremen K, et al. Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART) . EClinicalMedicine 2021; 40:101116.
Mohr R, Boesecke C, Dold L, Schierwagen R, Schwarze-Zander C, Wasmuth J-C, et al. Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis . Medicine 2018; 97:e0462.
Alqahtani SA, Schattenberg JM. Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice . Expert Rev Mol Diagn 2021; 21:1065–1078.
Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease . Gastroenterology 2019; 156:1717–1730.
Michel M, Schattenberg JM. Leberspezifische Diagnostik bei der nichtalkoholischen Fettlebererkrankung (NAFLD) - wann kann die Leberbiopsie ersetzt werden? [Liver-specific diagnostic for nonalcoholic fatty liver disease (NAFLD) - time to replace liver biopsy?] . Zeitschrift fur Gastroenterologie 2020; 58:1233–1240.
Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan W-K, et al. FibroScan-AST (FAST) score for the noninvasive identification of patients with nonalcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study . Lancet Gastroenterol Hepatol 2020; 5:362–373.
EASL-EASD-EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease . J Hepatol 2016; 64:1388–1402.
International Diabetes Federation (IDF). The IDF consensus worldwide definition of the metabolic syndrome. Available at: https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.html . [Accessed 12 December 2021]
Wong VW-S, Vergniol J, Wong GL-H, Foucher J, Chan HL-Y, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease . Hepatology 2010; 51:454–462.
Berzigotti A, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, Petta S, et al. EASL Clinical Practice Guidelines (CPGS) on non-invasive tests for evaluation of liver disease severity and prognosis- 2020 update . J Hepatol 2021; 75:659–689.
Pezzini MF, Cheinquer H, Araujo Ade, Schmidt-Cerski CT, Sprinz E, Herz-Wolff F, Poeta J. Hepatic steatosis among people living with HIV in Southern Brazil: prevalence and risk factors . Sci Rep 2020; 10:8282.
McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple noninvasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with nonalcoholic fatty liver disease . Gut 2010; 59:1265–1269.
Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD . Hepatology 2007; 45:846–854.
Sun W, Cui H, Li N, Wei Y, Lai S, Yang Y, et al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with nonalcoholic fatty liver disease: a meta-analysis study . Hepatol Res 2016; 46:862–870.
Lemoine M, Assoumou L, Wit Sde, Girard P-M, Valantin MA, Katlama C, et al. ANRS-ECHAM Group. Diagnostic accuracy of noninvasive markers of steatosis, NASH, and liver fibrosis in HIV-monoinfected individuals at risk of nonalcoholic fatty liver disease (NAFLD): results from the ECHAM Study . J Acquir Immune Defic Syndr 2019; 80:e86–e94.
Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts . BMC Med 2019; 17:95.
Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors . Hepatology 2010; 52:71–78.
Macías J, González J, Tural C, Ortega-González E, Pulido F, Rubio R, et al. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients . AIDS 2014; 28:1279–1287.
Yanavich C, Pacheco AG, Cardoso SW, Nunes EP, Chaves U, Freitas G, et al. Diagnostic value of serological biomarkers for detection of nonalcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV . HIV Med 2021; 22:445–456.
Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 . J Hepatol 2018; 69:896–904.
Guaraldi G, Squillace N, Stentarelli C, Orlando G, D’Amico R, Ligabue G, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors . Clin Infect Dis 2008; 47:250–257.
Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study . Hepatology 2005; 42:44–52.
Kirkegaard-Klitbo DM, Bendtsen F, Lundgren J, de Knegt RJ, Kofoed KF, Nielsen SD, Benfield T. Increased prevalence of liver fibrosis in people living with HIV without viral hepatitis compared to population controls . J Infect Dis 2020; 224:443–452.
Vermehren J, Vermehren A, Mueller A, Carlebach A, Lutz T, Gute P, et al. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers . BMC Gastroenterol 2012; 12:27.
Labenz C, Huber Y, Kalliga E, Nagel M, Ruckes C, Straub BK, et al. Predictors of advanced fibrosis in noncirrhotic nonalcoholic fatty liver disease in Germany . Aliment Pharmacol Ther 2018; 48:1109–1116.
Grant PM, Kitch D, McComsey GA, Collier AC, Bartali B, Koletar SL, et al. Long-term body composition changes in antiretroviral-treated HIV-infected individuals . AIDS 2016; 30:2805–2813.
Bravo AA, Sheth SG, Chopra S. Liver biopsy . New Engl J Med 2001; 344:495–500.